ChromaDex (NASDAQ:CDXC) Raised to Hold at Zacks Investment Research
ChromaDex (NASDAQ:CDXC – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, […]